博时上证科创板100ETF联接A（019857）基金经理为唐屹兵。 截至发稿，唐屹兵累计任职时间3年50天，现任基金资产总规模98.74亿元，任职期间最佳基金回报 87.2%， 任职期间最差基金回报-41.93%。 9月8日，心脉医疗涨5.34%，截至发稿，报112.50元/股，成交1.33亿元，换手率0.98%，总市值138.67亿 元。 资料显示，上海微创心脉医疗科技(集团)股份有限公司位于上海市浦东新区康新公路3399弄1号，成立 日期2012年8月17日，上市日期2019年7月22日，公司主营业务涉及主动脉及外周血管介入医疗器械的研 发、生产和销售。主营业务收入构成为：主动脉类71.94%，外周及其他28.04%，其他(补充)0.02%。 从心脉医疗十大流通股东角度 数据显示，博时基金旗下1只基金位居心脉医疗十大流通股东。博时上证科创板100ETF联接A （019857）二季度减持1.63万股，持有股数52.48万股，占流通股的比例为0.43%。根据测算，今日浮盈 赚取约299.15万元。 博时上证科创板100ETF联接A（019857）成立日期2023年12月1日，最新规模3.83亿。今年以来收益 ...

证券之星消息，截至2025年8月27日收盘，心脉医疗(688016)报收于112.1元，下跌5.22%，换手率 4.85%，成交量5.98万手，成交额6.88亿元。 8月27日的资金流向数据方面，主力资金净流出6301.95万元，占总成交额9.16%，游资资金净流入 695.91万元，占总成交额1.01%，散户资金净流入5606.04万元，占总成交额8.15%。 该股主要指标及行业内排名如下： 心脉医疗融资融券信息显示，融资方面，当日融资买入1.32亿元，融资偿还1.04亿元，融资净买入 2830.46万元。融券方面，融券卖出0.0股，融券偿还3700.0股，融券余量1.72万股，融券余额193.13万 元。融资融券余额5.79亿元。 近5日融资融券数据一览见下表： | 日期 | | 涨跌幅 融资余额(元) 融资净买入(元) 融券余量(股) | | | 融券净卖出(股) | 融资融券余额(元) | | --- | --- | --- | --- | --- | --- | --- | | 2025-08-27 | -5.22% | 5.77亿 | 2830.46万 | 1.72万 | -3700.0 | 5. ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-032 上海微创心脉医疗科技（集团）股份有限公司 关于 2025 年半年度募集资金存放与实际使用情况专 项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）印发的《上市公 司募集资金监管规则》（证监会公告[2025]10号）、《上海证券交易所科创板上 市公司自律监管指引第1号——规范运作》等相关法律法规的规定及要求，上海 微创心脉医疗科技（集团）股份有限公司（以下简称"公司"、"本公司"或"心脉 医疗"）董事会将公司2025年半年度募集资金存放与实际使用情况专项说明如下： 一、募集资金基本情况 （一）实际募集资金情况 根据上海微创心脉医疗科技（集团）股份有限公司2019年3月12日召开的第 一届董事会第三次会议决议和2019年3月27日召开的2019年第一次临时股东大会 决议，并于2019年7月2日经中国证券监督管理委员会《关于同意上海微创心脉医 疗科技股份有限公司首次公开发行股票注册的批复》（证监许可[ ...

证券之星消息，截至2025年8月12日收盘，心脉医疗(688016)报收于120.0元，上涨1.55%，换手率 3.4%，成交量4.19万手，成交额5.07亿元。 8月12日的资金流向数据方面，主力资金净流出3803.64万元，占总成交额7.51%，游资资金净流出 168.02万元，占总成交额0.33%，散户资金净流入3971.65万元，占总成交额7.84%。 近5日资金流向一览见下表： | 指标 | 心脉医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 147.91亿元 | 120.28亿元 | 23 123 | | 净资产 | 38.85亿元 | 38.99亿元 | 39 123 | | 净利润 | 1.3亿元 | 7927.36万元 | 18 123 | | 市盈率(动) | 28.52 | 69.5 | 27 123 | | 市净率 | 3.89 | 3.99 | 84 123 | | 毛利率 | 69.61% | 51.34% | 22 123 | | 净利率 | 38.53% | 10.86% | 5 123 | | ROE | 3. ...

Core Viewpoint - The stock of Xinmai Medical (688016) has shown fluctuations in trading volume and capital flow, with a recent closing price of 92.85 yuan, reflecting a 0.86% increase on July 8, 2025. The company is involved in the development, production, and sales of interventional medical devices for aortic and peripheral blood vessels [1][2]. Group 1: Stock Performance and Capital Flow - As of July 8, 2025, Xinmai Medical's stock closed at 92.85 yuan, with a trading volume of 12,100 hands and a total transaction amount of 112 million yuan [1]. - On July 8, the net outflow of main funds was 666,600 yuan, accounting for 0.59% of the total transaction amount, while retail investors experienced a net outflow of 5.31 million yuan, representing 4.74% of the total [1]. - Over the past five days, the stock has seen varying capital flows, with significant net inflows from speculative funds on certain days, indicating fluctuating investor sentiment [1]. Group 2: Financial Metrics and Industry Comparison - Xinmai Medical's total market value is 11.445 billion yuan, slightly above the industry average of 10.691 billion yuan, ranking 28th out of 122 companies in the medical device sector [2]. - The company reported a net profit of 130 million yuan for Q1 2025, a decrease of 29.66% year-on-year, with a gross margin of 69.61%, significantly higher than the industry average of 51.08% [2]. - The company's return on equity (ROE) stands at 3.19%, outperforming the industry average of 1.01%, indicating better profitability relative to equity [2].

Group 1 - Milkwater has evolved from its beginnings in Pudong in 1998 to become a leading player in the chemical and new energy supply chain industry, expanding its operations globally to regions including Asia-Pacific, the United States, North Africa, and Eastern Europe, with over 300 overseas employees [1] - The company aims to increase its overseas business to over 40% within the next 10 years, leveraging Pudong as a base for global expansion [1] - The trend of Chinese enterprises "going global" is supported by Pudong's comprehensive advantages, including institutional innovation and a robust service platform for companies to expand internationally [3] Group 2 - Milkwater showcased its integrated services in chemical and new energy supply chains at major exhibitions in Germany, marking significant steps in its global expansion efforts [4] - The company has engaged in deep cooperation discussions with international transport giants and local supply chain service providers in Brazil, indicating its strategic move into the South American market [4] - Data from Ernst & Young indicates that from 2020 to 2024, China's outbound investment is expected to rise by 22%, significantly outpacing the global growth rate of 7%, highlighting the rapid internationalization of Chinese enterprises [4] Group 3 - Heartbeat Medical, established in the Shanghai International Medical Park, has become a leader in the field of vascular intervention, with 30 products available globally and a strong pipeline of innovative medical devices [5] - The company has made significant investments in the U.S., Netherlands, and the UK, achieving an annual compound growth rate of over 60% in overseas revenue over the past five years [7] - Heartbeat Medical's acquisition of Lombard Medical is seen as a key milestone in its global strategy, enhancing its presence in the European market [7] Group 4 - The supportive business environment in Pudong has been crucial for Heartbeat Medical's international expansion, with streamlined processes for overseas investment and various policy measures to facilitate growth [8] - Pudong has introduced comprehensive support measures for outbound enterprises, including financial support, talent services, and operational assistance, to enhance their international competitiveness [8][9] - The establishment of the Pudong Outbound Enterprise Comprehensive Service Center aims to provide a full range of services for companies looking to expand globally, reducing risks and costs associated with international operations [10][11] Group 5 - Numerous projects from national enterprises are emerging in Pudong, including international manufacturing facilities and supply chain initiatives, showcasing the region's role as a launchpad for global strategies [10] - The Pudong Outbound Enterprise Comprehensive Service Center collaborates with various partners to offer extensive support, from market research to operational assistance, facilitating smoother international ventures for companies [11] - The growing ecosystem in Pudong is attracting high-quality enterprises nationwide, creating a collaborative environment for shared resources and expertise in global expansion [11]

Group 1 - The company, Ying Tai Medical, has entered into a formal acquisition agreement to acquire a total of 81.83% equity in Hangzhou Weiqiang Medical Technology Co., Ltd. for approximately RMB 513 million, with the company acquiring 51.70% controlling interest for about RMB 324 million [1] - The acquisition is conditional and will only be finalized upon the completion or waiver of certain preconditions [1] - Following the acquisition, the target company will become a non-wholly owned subsidiary of Ying Tai Medical, and the company along with Chen Yue Weixin will inject no less than RMB 150 million into the target company [1] Group 2 - The target company specializes in the research, development, manufacturing, and sales of peripheral vascular interventional medical devices, which is a significant area of focus for the company's industry layout [2] - The acquisition is aimed at enhancing the company's product portfolio in the aortic and peripheral vascular interventional and implantable device sectors [2]